Ozempic vs Wegovy vs Mounjaro vs Trulicity: Which GLP-1 Drug Is Best for Weight Loss and Diabetes in 2026?

GLP-1 & Obesity Medicine Guide • Updated October 2026

Ozempic, Wegovy, Mounjaro and Trulicity are all once-weekly injectable medicines, but they are not the same drug and they are not approved for exactly the same purposes. Ozempic and Wegovy contain semaglutide; Trulicity contains dulaglutide; and Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist.

For weight loss, the strongest head-to-head evidence currently favors tirzepatide over semaglutide. In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide versus 13.7% with semaglutide. For type 2 diabetes, tirzepatide has also produced greater weight loss and HbA1c reduction than semaglutide 1 mg in SURPASS-2, although that trial does not prove that tirzepatide is superior to every semaglutide dose or every patient-specific regimen.

At the same time, “best” depends on the goal. Semaglutide has extensive cardiovascular and kidney-outcome evidence, while dulaglutide has proven cardiovascular benefit in type 2 diabetes. Drug availability, contraindications, gastrointestinal tolerance, other medicines, kidney and heart disease, pregnancy plans, and insurance or local access can all change the practical choice.

OneDayMD bottom line: For average weight loss, tirzepatide is the current front-runner among these four molecules. For obesity treatment in the U.S., the relevant tirzepatide brand is Zepbound, not Mounjaro. For semaglutide, Wegovy is the obesity-labeled product, whereas Ozempic is labeled primarily for type 2 diabetes and diabetes-related cardiovascular/kidney risk reduction. Trulicity remains an important diabetes drug, but it is not the strongest of these four for weight loss.

In this guide

1. Quick comparison
2. Ozempic and Wegovy: same molecule, different role
3. How the four drugs work
4. Which works best for weight loss?
5. Which works best for type 2 diabetes?
6. Cardiovascular and kidney considerations
7. Typical U.S. dosing and escalation
8. Side effects and safety
9. Who may be a better fit for each medicine?
10. Can you switch from one to another?
11. Common myths and mistakes
12. FAQ
13. Key evidence and sources

Ozempic vs Wegovy vs Mounjaro vs Trulicity: Quick Comparison

Brand	Active ingredient	Hormone pathway	Main U.S. role	Adult maximum listed dose	Weight-loss strength
Ozempic	Semaglutide	GLP-1 receptor agonist	Type 2 diabetes; cardiovascular risk reduction in T2D with established CVD; kidney/CV risk reduction in T2D with CKD	2 mg once weekly	High
Wegovy	Semaglutide	GLP-1 receptor agonist	Chronic weight management; cardiovascular risk reduction in adults with CVD and overweight/obesity; MASH in selected adults under current U.S. labeling	2.4 mg once weekly	Very high
Mounjaro	Tirzepatide	GIP + GLP-1	Type 2 diabetes	15 mg once weekly	Very high
Trulicity	Dulaglutide	GLP-1 receptor agonist	Type 2 diabetes; cardiovascular risk reduction in T2D with established CVD or multiple CV risk factors	4.5 mg once weekly	Moderate

Important: these doses are not dose-equivalent. A 2 mg dose of semaglutide cannot be compared numerically with a 15 mg dose of tirzepatide or a 4.5 mg dose of dulaglutide. Dose escalation should follow the prescribing information and the patient's clinical response.

Regulatory note: This article uses current U.S. FDA labeling as the regulatory reference. Approvals, indications, doses, reimbursement and brand names can differ in Malaysia and other countries. A medicine being approved for type 2 diabetes does not automatically mean the same brand is approved for obesity.

Ozempic and Wegovy: Same Active Ingredient, Different Clinical Role

One of the most common GLP-1 misconceptions is that Ozempic and Wegovy are completely different drugs. They are not. Both contain semaglutide.

The major difference is the approved indication, labeled dose range and clinical program.

• Ozempic: semaglutide for glycemic control in adults with type 2 diabetes, with current U.S. indications that also include reduction of major cardiovascular events in adults with T2D and established cardiovascular disease and reduction of certain kidney/CV outcomes in adults with T2D and chronic kidney disease.
• Wegovy: semaglutide specifically labeled for chronic weight management in adults and in adolescents aged 12 years and older with obesity, certain adults with overweight and a weight-related condition, and additional cardiovascular and liver-related indications under current U.S. labeling.

So it is misleading to ask whether Ozempic is “stronger” than Wegovy. The active molecule is the same. The clinical context and labeled dosing are different.

FDA: Ozempic prescribing information • FDA: Wegovy prescribing information

How Do Ozempic, Wegovy, Mounjaro and Trulicity Work?

Ozempic and Wegovy: semaglutide

Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin hormone involved in glucose regulation and appetite signaling. GLP-1 receptor agonists increase glucose-dependent insulin secretion, reduce glucagon secretion when glucose is elevated, slow gastric emptying and reduce energy intake through effects on appetite and satiety.

Trulicity: dulaglutide

Dulaglutide is also a GLP-1 receptor agonist. It acts through the same broad incretin pathway as semaglutide but has a different molecular structure and pharmacologic profile. Its clinical weight-loss effect is generally smaller than that seen in obesity trials of higher-dose semaglutide or tirzepatide.

Mounjaro: tirzepatide

Tirzepatide is different because it activates both the GIP receptor and the GLP-1 receptor. The dual mechanism is one reason tirzepatide has become a major competitor to semaglutide in both diabetes and obesity medicine.

The distinction matters: Mounjaro is not simply a stronger version of Ozempic. It is a different molecule acting at two incretin receptors rather than one.

FDA: Mounjaro prescribing information • DailyMed: Trulicity prescribing information

Which Works Best for Weight Loss?

For the specific question of average weight loss, the strongest direct evidence among these four drugs points toward tirzepatide.

1. Tirzepatide vs semaglutide: the head-to-head trial

The most important modern comparison is SURMOUNT-5, a phase 3b randomized trial of adults with obesity or overweight and a weight-related condition, without type 2 diabetes.

At 72 weeks:

Outcome	Tirzepatide	Semaglutide
Mean body-weight change	−20.2%	−13.7%
Mean waist-circumference change	−18.4 cm	−13.0 cm
At least 10% weight loss	81.6%	60.5%
At least 15% weight loss	64.6%	40.1%
At least 20% weight loss	48.4%	27.3%

The trial used each drug at its maximum tolerated study dose: tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg weekly. Tirzepatide was superior for the primary weight endpoint and for the major weight-loss thresholds.

Evidence grade: E5 — high-level randomized, head-to-head clinical evidence for this specific comparison.

NEJM: SURMOUNT-5 — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

2. How effective is semaglutide for obesity?

Semaglutide is still a highly effective obesity medicine. In the landmark STEP 1 trial, adults with overweight or obesity without diabetes receiving semaglutide 2.4 mg plus lifestyle intervention had a mean body-weight reduction of 14.9% at 68 weeks, compared with 2.4% with placebo.

That result established semaglutide as a major step forward in pharmacologic obesity treatment. The newer SURMOUNT-5 trial simply shows that, when directly compared at maximum tolerated doses in a similar obesity population without diabetes, tirzepatide produced more weight loss on average.

Evidence grade: E5 — randomized placebo-controlled evidence for semaglutide 2.4 mg in obesity.

NEJM: STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or Obesity

3. What about Trulicity?

Trulicity can reduce body weight, but the magnitude is typically smaller than the weight loss seen in modern obesity trials of semaglutide or tirzepatide.

In AWARD-11, adults with type 2 diabetes inadequately controlled with metformin were randomized to dulaglutide 1.5 mg, 3 mg or 4.5 mg. At 36 weeks, mean weight changes were approximately −3.1 kg, −4.0 kg and −4.7 kg, respectively.

That does not make dulaglutide “weak.” It means the drug's clinical development and approved role are primarily centered on type 2 diabetes and cardiovascular risk reduction, rather than the level of weight reduction targeted by modern anti-obesity regimens.

Evidence grade: E5 — randomized trial evidence for dulaglutide dose escalation in type 2 diabetes.

PubMed: AWARD-11 weight analysis

Weight-loss ranking, based on current comparative evidence:
1 Tirzepatide — strongest head-to-head weight-loss evidence
2 Semaglutide — very strong obesity evidence
3 Dulaglutide — effective for diabetes, but generally less weight loss

Important limitation: this is an evidence ranking of average trial outcomes, not a guarantee for an individual. Some people lose much more or much less than the trial average. Tolerability, adherence, dose achieved, nutrition, physical activity, sleep, baseline weight and other medical conditions all matter.

Which Is Best for Type 2 Diabetes?

For type 2 diabetes, the question becomes more complicated because the goal is not simply “lose as much weight as possible.” The priorities may include HbA1c reduction, avoiding hypoglycemia, weight management, cardiovascular risk, kidney disease, side effects, treatment burden and compatibility with other medications.

Tirzepatide vs semaglutide in diabetes

In SURPASS-2, adults with type 2 diabetes receiving tirzepatide 5 mg, 10 mg or 15 mg had greater reductions in HbA1c and body weight than those receiving semaglutide 1 mg weekly over 40 weeks.

At 40 weeks	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
Mean weight change	−7.6 kg	−9.3 kg	−11.2 kg	−5.7 kg

However, a crucial editorial point is often missed online: SURPASS-2 compared tirzepatide with semaglutide 1 mg, not with the 2 mg Ozempic regimen and not with 2.4 mg Wegovy used for obesity. That means it supports a strong tirzepatide advantage over the studied semaglutide dose, but it should not be presented as a perfect head-to-head comparison of every possible semaglutide regimen.

Evidence grade: E5 — randomized active-comparator trial.

NEJM: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Semaglutide vs dulaglutide

SUSTAIN-7 directly compared semaglutide with dulaglutide in type 2 diabetes. Semaglutide produced greater reductions in both HbA1c and body weight at the doses tested.

At the higher-dose comparison used in that study, semaglutide 1.0 mg produced approximately 6.5 kg of mean weight loss versus about 3.0 kg with dulaglutide 1.5 mg at week 40. Semaglutide also produced a greater HbA1c reduction.

Evidence grade: E5 — randomized head-to-head evidence.

PubMed: SUSTAIN-7 — Semaglutide versus dulaglutide

Practical diabetes conclusion

If the primary problem is type 2 diabetes with obesity or substantial weight-related metabolic disease, tirzepatide and semaglutide are often the most compelling options among these four on glucose and weight outcomes. But “most potent” does not automatically mean “best for you.” A patient with a specific cardiovascular or kidney profile may appropriately favor a drug with the relevant outcome evidence and label.

Cardiovascular and Kidney Considerations

This is where a simple weight-loss ranking can become misleading.

Ozempic: diabetes, cardiovascular disease and chronic kidney disease

Under the current U.S. Ozempic label, semaglutide is indicated for glycemic control in adults with type 2 diabetes and also for:

• reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and
• reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Semaglutide has a substantial cardiovascular evidence base. In SUSTAIN-6, the primary cardiovascular composite outcome occurred less often with semaglutide than placebo, with a hazard ratio of 0.74. Later kidney-outcome evidence further strengthened the role of semaglutide in diabetes-associated CKD.

Evidence grade: E5 — randomized outcomes evidence.

PubMed: SUSTAIN-6 cardiovascular outcomes • FDA: current Ozempic label

Wegovy: obesity plus cardiovascular risk reduction

Wegovy has a distinct cardiovascular role. The current U.S. label includes reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.

This is clinically important because treating obesity is not only about the number on the scale. Weight reduction can interact with blood pressure, glycemic control, sleep apnea, fatty liver disease, mobility and overall cardiometabolic risk.

Evidence grade: E5 — randomized cardiovascular-outcomes evidence supporting the labeled indication.

FDA: current Wegovy label

Trulicity: cardiovascular risk reduction in type 2 diabetes

Trulicity also has cardiovascular-outcomes evidence. In the REWIND trial, dulaglutide reduced the risk of the primary composite cardiovascular endpoint compared with placebo, with a hazard ratio of 0.88.

This makes dulaglutide much more than a glucose-lowering drug. It has an established role in cardiovascular risk management for appropriate patients with type 2 diabetes.

Evidence grade: E5 — large randomized cardiovascular-outcomes trial.

PubMed: REWIND cardiovascular outcomes

Do not turn outcome trials into a simple “drug A beats drug B” scoreboard. Cardiovascular and kidney trials enroll different populations, use different comparators and have different endpoints. A cardiovascular benefit demonstrated for one indication does not automatically mean the same magnitude of benefit exists in every person using the drug for weight loss.

Typical U.S. Dosing and Dose Escalation

All four medicines are administered once weekly, but their titration schedules are different. The starting dose is intentionally low for several of these drugs to improve tolerability, particularly gastrointestinal tolerability.

Drug	Typical initiation	Typical escalation	Adult maximum
Ozempic	0.25 mg weekly for 4 weeks	0.5 mg → 1 mg → 2 mg, with at least 4 weeks at each step when increased	2 mg weekly
Wegovy	0.25 mg weekly for 4 weeks	0.5 mg → 1 mg → 1.7 mg → 2.4 mg, generally advancing every 4 weeks as tolerated	2.4 mg weekly
Mounjaro	2.5 mg weekly for 4 weeks	5 mg, then increases of 2.5 mg after at least 4 weeks on the current dose when additional control is needed	15 mg weekly
Trulicity	0.75 mg weekly	1.5 mg, then 3 mg and 4.5 mg in selected adults when additional glycemic control is needed	4.5 mg weekly

These are label summaries, not personalized dosing instructions. Do not accelerate titration because weight loss seems slow, and do not change doses without the prescribing clinician.

Current FDA labels also emphasize important administration and safety details, including once-weekly dosing, injection-site options, missed-dose instructions, and interactions with insulin or insulin secretagogues.

Side Effects: Are Mounjaro, Ozempic, Wegovy and Trulicity Similar?

Broadly, yes. The most common adverse effects across the class are gastrointestinal:

• nausea
• vomiting
• diarrhea
• constipation
• abdominal pain or discomfort
• decreased appetite
• dyspepsia or related upper-GI symptoms

GI symptoms are often most noticeable during dose escalation and may improve over time. The solution is not always to stop treatment; clinicians can sometimes pause escalation, return to a previously tolerated dose, or reassess whether another medicine is more suitable.

Important serious warnings

The prescribing information for these products includes warnings or precautions relating to conditions such as acute pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycemia when combined with insulin or insulin-secretagogue therapy, serious hypersensitivity reactions and severe gastrointestinal reactions. The labels also contain warnings about pulmonary aspiration during general anesthesia or deep sedation.

All four products carry a boxed warning concerning thyroid C-cell tumors based on rodent findings and are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

The labeling does not establish that these medicines cause MTC in humans. The human relevance of the rodent finding remains unknown, which is why the contraindication exists.

Ozempic FDA label • Wegovy FDA label • Mounjaro FDA label • Trulicity DailyMed label

What about diabetic retinopathy?

Semaglutide labeling includes a warning about diabetic retinopathy complications, particularly in patients with a history of diabetic retinopathy. Rapid improvement in glucose levels can sometimes be accompanied by transient worsening of diabetic retinopathy, so people with established diabetic eye disease should discuss monitoring with their clinician.

What about pregnancy?

These medicines are generally not used for routine weight-loss treatment during pregnancy. Semaglutide labeling recommends discontinuing it at least 2 months before a planned pregnancy because of its long half-life.

Tirzepatide also has a practical contraception issue: because it can affect gastric emptying, the Mounjaro label advises people using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method for a specified period after starting tirzepatide and after dose escalations.

Seek urgent medical attention for symptoms such as severe or persistent abdominal pain, especially if it radiates to the back; repeated vomiting with dehydration; severe allergic symptoms; severe weakness or confusion associated with low blood glucose; or other symptoms that your clinician has told you may represent a serious adverse reaction.

Who May Be a Better Fit for Each Medicine?

1 Wegovy — when obesity treatment is the primary goal

Potential advantage: it is specifically labeled for chronic weight management and has substantial obesity and cardiovascular-outcomes evidence.

Wegovy may be especially relevant when the clinical goal is long-term weight reduction rather than diabetes treatment alone.

2 Mounjaro — when type 2 diabetes plus major weight reduction is the goal

Potential advantage: tirzepatide has exceptionally strong glucose-lowering and weight-loss effects and activates both GIP and GLP-1 receptors.

For obesity without diabetes in the United States, remember the brand distinction: Zepbound contains the same tirzepatide molecule and is the obesity indication.

3 Ozempic — when type 2 diabetes with cardiovascular or kidney considerations is central

Potential advantage: semaglutide has a mature evidence base spanning glycemic control, cardiovascular outcomes and kidney outcomes, and the current U.S. Ozempic label reflects those indications.

4 Trulicity — when established diabetes treatment and cardiovascular evidence matter

Potential advantage: dulaglutide is a well-established once-weekly diabetes therapy with cardiovascular-outcomes evidence and pediatric labeling in the United States. Its weight-loss effect is generally more modest than semaglutide or tirzepatide.

The practical lesson: the “best” GLP-1-based medicine is often the one that gives the desired metabolic benefit and can be taken consistently at a tolerated dose without creating unacceptable risk or treatment burden.

Can You Switch from Ozempic to Wegovy, Mounjaro or Trulicity?

Patients sometimes switch between these medicines because of inadequate response, side effects, supply, cost, insurance coverage or a change in treatment goals. But switching should not be treated as a simple milligram-for-milligram conversion.

Semaglutide and tirzepatide do not have interchangeable dose scales. A clinician may choose a new starting dose based on the previous drug, the time since the last dose, the patient's tolerance and the risk of gastrointestinal adverse effects.

Switching also creates an opportunity to review:

• current HbA1c and fasting glucose
• weight trajectory and waist circumference
• blood pressure and lipid risk
• kidney function
• gallbladder and gastrointestinal symptoms
• nutrition, protein intake and physical activity
• muscle and functional status during weight loss
• other glucose-lowering medicines that can cause hypoglycemia

That last point is important. Weight loss is not the same thing as healthy body-composition change. A strong obesity-treatment program should also consider protein adequacy, resistance exercise, micronutrient intake, sleep and preservation of muscle function.

See the OneDayMD GLP-1 resource hub for related guides on dosing, nutrition, adverse effects, peptides and long-term treatment strategy.

Common Myths About Ozempic, Wegovy, Mounjaro and Trulicity

Myth 1: “Ozempic and Wegovy are different drugs.”

Reality: they both contain semaglutide. The indication and dosing framework differ.

Myth 2: “Mounjaro is just a stronger GLP-1.”

Reality: tirzepatide is a dual GIP/GLP-1 receptor agonist.

Myth 3: “Trulicity does not cause weight loss.”

Reality: dulaglutide can reduce body weight, but the average effect is generally smaller than with semaglutide 2.4 mg or tirzepatide in dedicated obesity trials.

Myth 4: “More weight loss is automatically better.”

Reality: a medication should be judged by its overall benefit-risk profile, not just the percentage on the scale. Losing weight while becoming nutritionally depleted, dehydrated or functionally weaker is not the goal.

Myth 5: “You can compare the doses directly.”

Reality: 15 mg of tirzepatide is not “stronger than” 2 mg of semaglutide simply because the number is larger. These molecules are different and have different pharmacology.

Best Drug by Goal in 2026

Clinical goal	Leading option among these four	Why	Important caveat
Maximum average weight loss	Tirzepatide	Superior to semaglutide in SURMOUNT-5	For U.S. obesity treatment, the obesity brand is Zepbound
FDA-labeled chronic obesity treatment	Wegovy	Semaglutide is specifically labeled for chronic weight management	Patient eligibility and local approval vary
Type 2 diabetes + substantial weight loss	Mounjaro / tirzepatide is often highly compelling	Strong HbA1c and weight results in randomized trials	Individual cardiovascular/kidney profile still matters
Type 2 diabetes + established CVD	Several options have outcome evidence	Ozempic and Trulicity have diabetes CV-outcome indications; Wegovy has a specific obesity/CVD indication	Do not choose solely from a headline ranking
Type 2 diabetes + CKD	Ozempic is especially notable	Current U.S. labeling includes a kidney/CV risk-reduction indication	CKD management should be individualized
More modest weight effect but established diabetes role	Trulicity	Long clinical experience and cardiovascular-outcomes evidence	Usually not the leading choice when maximal weight loss is the primary objective

Evidence Grade: How Strong Is the Comparison?

OneDayMD uses an evidence hierarchy to prevent marketing language from being confused with clinical proof.

Grade	Meaning used in this article	Examples here
E5	High-level randomized clinical evidence, including head-to-head trials or major outcomes trials	SURMOUNT-5, SURPASS-2, SUSTAIN-7, REWIND
E4	Strong secondary analysis or consistent randomized-trial evidence	Some subgroup or post-hoc outcome analyses
E3	Prospective observational or lower-certainty clinical evidence	Some real-world comparisons
E2	Retrospective, mechanistic or indirect clinical evidence	Selected database analyses
E1	Preclinical or hypothesis-generating evidence	Animal or laboratory findings
E0	Anecdote, testimonial, marketing claim or unsupported assertion	Social-media “before and after” stories without clinical verification

The strongest conclusion in this article is therefore not based on internet popularity. It is based on randomized evidence: tirzepatide beat semaglutide for weight loss in SURMOUNT-5, semaglutide beat dulaglutide in SUSTAIN-7, and dulaglutide demonstrated cardiovascular benefit in REWIND.

Ozempic vs Wegovy vs Mounjaro vs Trulicity: FAQ

Is Mounjaro better than Ozempic for weight loss?

On average, tirzepatide produces more weight loss than semaglutide in direct comparisons. SURMOUNT-5 showed 20.2% versus 13.7% mean weight loss at 72 weeks in adults with obesity without diabetes. However, that trial compared tirzepatide with obesity-dose semaglutide and does not mean every individual will respond better to tirzepatide.

Is Wegovy stronger than Ozempic?

Wegovy and Ozempic contain the same active ingredient, semaglutide. Wegovy is the semaglutide product specifically labeled in the U.S. for chronic weight management and uses a higher obesity-maintenance dose of 2.4 mg weekly. Ozempic is primarily a type 2 diabetes product in the U.S. with a maximum labeled adult dose of 2 mg weekly.

Which is better for diabetes: Mounjaro or Ozempic?

Tirzepatide has shown greater HbA1c and weight reduction than semaglutide 1 mg in SURPASS-2. But the best drug for a particular patient depends on more than HbA1c. Cardiovascular disease, CKD, hypoglycemia risk, side effects, other medicines and treatment goals all matter.

Which causes the least weight loss: Trulicity or Ozempic?

Dulaglutide generally produces less weight loss than semaglutide in direct or cross-trial comparisons. In SUSTAIN-7, semaglutide produced greater weight loss than dulaglutide at the studied doses.

Can Ozempic and Wegovy be taken together?

No. They both contain semaglutide. The Wegovy label specifically states that coadministration with other semaglutide-containing products or another GLP-1 receptor agonist is not recommended.

Can Mounjaro be used for weight loss?

Tirzepatide is highly effective for weight loss. In the United States, however, Mounjaro is the diabetes brand, while Zepbound is the tirzepatide brand approved for chronic weight management. Local approvals can differ.

Do these drugs cause muscle loss?

Weight loss from incretin medicines includes both fat and lean mass. The amount of lean-mass loss varies between studies and individuals. Preserving muscle should therefore be treated as part of the obesity-treatment plan through adequate protein intake, resistance training and appropriate monitoring rather than assuming that a larger scale-weight reduction is automatically healthier.

What happens when you stop a GLP-1 drug?

Weight regain is common after stopping effective anti-obesity medication, although the degree varies. Obesity is a chronic disease, and long-term treatment planning should be discussed before assuming that a successful medication course will automatically be permanent after discontinuation.

Which one is best overall?

There is no universal winner. Tirzepatide currently has the strongest average weight-loss performance, semaglutide has a broad obesity and cardiometabolic evidence base, and dulaglutide remains a well-established diabetes therapy with cardiovascular-outcomes evidence. The best choice is the one whose benefits, risks and practical use fit the individual's clinical profile.

Key Evidence and Primary Sources

1. SURMOUNT-5: Tirzepatide compared with semaglutide for obesity. New England Journal of Medicine, 2025. View study.
2. SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes. New England Journal of Medicine, 2021. View study.
3. STEP 1: Semaglutide 2.4 mg in adults with overweight or obesity. New England Journal of Medicine, 2021. View study.
4. SUSTAIN-7: Semaglutide versus dulaglutide in type 2 diabetes. Lancet Diabetes & Endocrinology, 2018. PubMed.
5. AWARD-11: Dulaglutide 3.0 mg and 4.5 mg in type 2 diabetes. PubMed.
6. REWIND: Dulaglutide and cardiovascular outcomes in type 2 diabetes. PubMed.
7. SUSTAIN-6: Semaglutide and cardiovascular outcomes in type 2 diabetes. PubMed.
8. FDA: Ozempic label, Wegovy label, and Mounjaro label.
9. DailyMed: Trulicity prescribing information.

Explore more OneDayMD GLP-1 research
Use the OneDayMD GLP-1 resource hub for additional evidence guides covering dose escalation, nutrient adequacy, muscle preservation, stopping GLP-1 drugs, emerging incretin therapies and practical treatment strategy.

OneDayMD Editorial Note

GLP-1-based medicines have changed the treatment landscape for obesity and type 2 diabetes, but internet discussion often collapses different molecules, brands and indications into one category. This article separates drug, mechanism, indication, dose and evidence so that readers can make a more informed decision with a qualified healthcare professional.

This article is educational and does not prescribe, diagnose or replace individualized medical care. Prescription decisions should be made with a qualified clinician who knows the patient's medical history, medications, laboratory data and treatment goals.

Last reviewed: October 2026. Regulatory basis: current U.S. FDA labeling available at the time of review, supplemented by peer-reviewed randomized clinical trials. Drug labels and approvals can change; readers outside the United States should consult the regulator and product information applicable in their country.